Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25251255 | 0.92 | BTK (0.45) | BTKLCKDGAT2 | |
| SCHEMBL29418468 | 0.90 | BTK (0.42) | BTKLCKPIK3CDDGAT2 | |
| SCHEMBL29418348 | 0.90 | BTK (0.43) | BTKLCKDGAT2 | |
| SCHEMBL25220113 | 0.90 | BTK (0.43) | BTKLCKDGAT2 | |
| SCHEMBL29418556 | 0.89 | PIK3CD (0.40) | BTKLCKPIK3CDKIF18ADGAT2 | |
| SCHEMBL29418421 | 0.89 | BTK (0.41) | BTKLCKPIK3CDKIF18ADGAT2 | |
| SCHEMBL29418487 | 0.89 | BTK (0.44) | BTKLCKPIK3CDKIF18AKDM4D | |
| SCHEMBL29418749 | 0.89 | BTK (0.44) | BTKLCKPIK3CDKIF18AKDM4D | |
| SCHEMBL29418646 | 0.88 | BTK (0.41) | BTKPIK3CDKIF18ADGAT2KDM4D | |
| SCHEMBL29418623 | 0.88 | BTK (0.41) | BTKPIK3CDKIF18ADGAT2KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885LCK 7/4885PIK3CD 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.